-
The British Journal of Dermatology Jan 2010
Topics: Administration, Oral; Adult; Alitretinoin; Chronic Disease; Dermatitis, Atopic; Dermatologic Agents; Female; Hand Dermatoses; Humans; Male; Middle Aged; Treatment Outcome; Tretinoin; Young Adult
PubMed: 19886882
DOI: 10.1111/j.1365-2133.2009.09522.x -
Journal of the European Academy of... May 2016
Topics: Aged; Alitretinoin; Amyloidosis, Familial; Humans; Male; Skin Diseases, Genetic; Tretinoin
PubMed: 25715817
DOI: 10.1111/jdv.13048 -
Dermatologic Therapy 2016
Topics: Administration, Oral; Adolescent; Alitretinoin; Dermatologic Agents; Humans; Male; Pityriasis Rubra Pilaris; Treatment Outcome; Tretinoin
PubMed: 26556472
DOI: 10.1111/dth.12320 -
Circulation Feb 2012
Topics: Alitretinoin; Animals; Lymphangiogenesis; Lymphatic Vessels; Lymphedema; Regeneration; Tretinoin
PubMed: 22275500
DOI: 10.1161/CIRCULATIONAHA.111.083477 -
Archives of Dermatology Dec 2004To assess the efficacy and safety of oral alitretinoin (9-cis-retinoic acid), 10 mg/d, 20 mg/d, and 40 mg/d, compared with placebo control, in the treatment of chronic... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial.
OBJECTIVE
To assess the efficacy and safety of oral alitretinoin (9-cis-retinoic acid), 10 mg/d, 20 mg/d, and 40 mg/d, compared with placebo control, in the treatment of chronic hand dermatitis.
DESIGN
Multicenter, randomized, double-blind, placebo-control, prospective trial.
SETTING
A total of 43 outpatient clinics in 10 European countries.
PATIENTS
Of 348 patients screened, 319 with moderate or severe refractory chronic hand dermatitis were randomized, in the ratio of 1:1:1:1, to 4 treatment groups and received allocated intervention. Of 75 patients who withdrew, 24 withdrew owing to adverse events.
INTERVENTIONS
Placebo or 10 mg, 20 mg, or 40 mg of oral alitretinoin (9-cis-retinoic acid) taken once daily for 12 weeks. Safety was assessed for all patients during a follow-up period of 4 weeks, and responders were observed for a follow-up period of 3 months.
MAIN OUTCOME MEASURE
Physician's global assessment of overall chronic hand dermatitis severity.
RESULTS
Alitretinoin led to a significant and dose-dependent improvement in disease status, with responses in up to 53% of patients, and up to a 70% mean reduction in disease signs and symptoms. Treatment was generally well tolerated, with dose-dependent effects comprising headache, flushing, mucocutaneous events, hyperlipidemia, and decreased hemoglobin and decreased free thyroxin levels. Three months after discontinuation of treatment, the rate of relapse was 26%, independent of dose.
CONCLUSION
Alitretinoin given at well-tolerated doses induced substantial clearing of chronic hand dermatitis in patients refractory to conventional therapy.
Topics: Administration, Oral; Adrenal Cortex Hormones; Alitretinoin; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Hand Dermatoses; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Treatment Outcome; Tretinoin
PubMed: 15611422
DOI: 10.1001/archderm.140.12.1453 -
Giornale Italiano Di Dermatologia E... Apr 2016
Topics: Adult; Alitretinoin; Dermatologic Agents; Eczema; Follow-Up Studies; Hand Dermatoses; Headache; Humans; Male; Time Factors; Tretinoin
PubMed: 26449913
DOI: No ID Found -
European Journal of Dermatology : EJD Feb 2019Chronic hand eczema is an inflammatory dermatosis that results in a significant psychological and socio-economic burden. Alitretinoin (AL) is indicated in adults with... (Observational Study)
Observational Study
BACKGROUND
Chronic hand eczema is an inflammatory dermatosis that results in a significant psychological and socio-economic burden. Alitretinoin (AL) is indicated in adults with severe chronic hand eczema (sCHE) unresponsive to potent topical corticosteroids.
OBJECTIVES
To assess AL effectiveness and safety in patients with sCHE under real-life conditions based on a prospective observational study in France (2010-2014).
MATERIALS & METHODS
Clinical severity was assessed using Physician Global Assessment (PGA) and Modified Total Lesion Symptom Score (mTLSS) and quality of life by Skindex and visual analogue scales. Patients were treated with AL for 12-24 weeks and followed for 24 months. Responders were patients with clear/almost clear skin based on PGA at the end of treatment and the primary outcome was remission (clear, almost clear, or mild skin) at one and two years after treatment.
RESULTS
A total of 394 patients with severe or moderate PGA were included in the study by 109 dermatologists. AL treatment duration was 5.4 ± 4.1 months (mean ± SD) and 112/274 patients evaluated at the end of treatment were responders. Of the 112 responders, 41/51 evaluable patients were in remission after one year and 36/46 after two years. At the end of treatment, Skindex improved from 48.8 ± 18.1% to 27.1 ± 23.2%. Among the 112 responders, 68/84 did not relapse (mTLSS increased >75% from baseline). The most common adverse events were headache (24%) and dyslipidaemia (4%).
CONCLUSIONS
This study supports a positive benefit/risk profile for AL for sCHE patients unresponsive to topical corticosteroids.
Topics: Administration, Oral; Alitretinoin; Dermatologic Agents; Eczema; Female; France; Hand Dermatoses; Humans; Male; Middle Aged; Quality of Life
PubMed: 30827949
DOI: 10.1684/ejd.2018.3484 -
Journal of the European Academy of... Nov 2017
Topics: Administration, Oral; Adult; Aged; Alitretinoin; Dermatologic Agents; Female; Humans; Male; Porokeratosis
PubMed: 28543730
DOI: 10.1111/jdv.14354 -
Acta Dermato-venereologica Jan 2020
Topics: Administration, Oral; Alitretinoin; Chronic Disease; Cyclosporine; Dermatologic Agents; Eczema; Hand Dermatoses; Humans; Patient Safety; Retrospective Studies; Skin; Time Factors; Treatment Outcome
PubMed: 31821516
DOI: 10.2340/00015555-3392 -
Dermatitis : Contact, Atopic,... 2013Chronic hand eczema (CHE) is a common disease that has a major impact on patients' health and on society. (Observational Study)
Observational Study
UNLABELLED
Chronic hand eczema (CHE) is a common disease that has a major impact on patients' health and on society.
AIM
The purpose of this observational, open-label study was to assess the efficacy of treatment with 30 mg/d of oral alitretinoin on the quality of life (QoL) in a group of patients affected by CHE.
METHODS
This study included 15 patients, all suffering from severe CHE refractory to treatment with potent topical corticosteroids, who underwent treatment with 30 mg/d of alitretinoin for a period of 3 months. At the 1- and 3-month points, together with a clinical evaluation, the QoL of these patients were evaluated by the Dermatology Life Quality Index and visual analog scale (EQ5D-VAS).
RESULTS
The oral administration of alitretinoin led to a notable QoL improvement among the patients, as shown by the statistically significant improvement in the Dermatology Life Quality Index and in the EQ5D-VAS after 1 and 3 months of therapy.
Topics: Administration, Oral; Adult; Alitretinoin; Chronic Disease; Dermatologic Agents; Eczema; Female; Follow-Up Studies; Hand Dermatoses; Headache; Humans; Male; Middle Aged; Pain Measurement; Quality of Life; Treatment Outcome; Tretinoin
PubMed: 23857016
DOI: 10.1097/DER.0b013e3182987773